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Detection of AmpC beta-lactamase in Escherichia coli:
comparison of three phenotypic confirmation assays and genetic
analysis
Abstract
Two mechanisms account for AmpC activity in E. coli: mutations in the ampC promoter and attenuator
regions resulting in ampC overexpression and/or acquisition of plasmid-encoded ampC genes. In this
study we analyzed 51 clinical E. coli isolates with reduced susceptibility to amoxicillin/clavulanic acid,
piperacillin/tazobactam or third generation cephalosporins for the presence of AmpC production. Three
phenotypic AmpC confirmation assays (cefoxitin/cloxacillin disk diffusion test, cefoxitin/EDTA disk
diffusion test, AmpC ETest) were compared for the detection of AmpC activity. All 51 isolates were
genetically characterized by mutation analysis of the chromosomal ampC promoter/attenuator region
and by PCR detection of plasmid-encoded ampC genes. Altogether, 21/51 (41 %) E. coli isolates were
considered true AmpC producers. AmpC activity due to chromosomal ampC promoter/attenuator
mutations was found in 12/21 strains, plasmid-encoded ampC genes were detected in 8/21 isolates. 1/21
strains contained both, ampC promoter mutations and a plasmid-encoded ampC gene. All three
phenotypic tests were able to detect the majority (>90%) of AmpC positive strains correctly. Cefoxitin
resistance was found to be a discriminative parameter, detecting 20/21 AmpC producing strains.
Susceptibility to third generation cephalosporines, e.g. ceftriaxone, cetazidime and cefotaxime, was
found in 9 of the 21 AmpC positive strains. When considering the elevated zone diameter breakpoints of
the 2010 CLSI guidelines 2/21 AmpC positive strains were categorized susceptible to third generation
cephalosporines.
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Abstract 16 
Two mechanisms account for AmpC activity in E. coli:  mutations in the ampC promoter and 17 
attenuator regions resulting in ampC overexpression and/or acquisition of plasmid-encoded 18 
ampC genes. In this study we analyzed 51 clinical E. coli isolates with reduced susceptibility to 19 
amoxicillin/clavulanic acid, piperacillin/tazobactam or third generation cephalosporins for the 20 
presence of AmpC production. Three phenotypic AmpC confirmation assays (cefoxitin/cloxacillin 21 
disk diffusion test, cefoxitin/EDTA disk diffusion test, AmpC ETest) were compared for the 22 
detection of AmpC activity. All 51 isolates were genetically characterized by mutation analysis of 23 
the chromosomal ampC promoter/attenuator region and by PCR detection of plasmid-encoded 24 
ampC genes. Altogether, 21/51 (41 %)  E. coli isolates were considered true AmpC producers. 25 
AmpC activity due to chromosomal ampC promoter/attenuator mutations was found in 12/21 26 
strains, plasmid-encoded ampC genes were detected in 8/21 isolates. 1/21 strains contained 27 
both, ampC promoter mutations and a plasmid-encoded ampC gene. All three phenotypic tests 28 
were able to detect the majority (>90%) of AmpC positive strains correctly. Cefoxitin resistance 29 
was found to be a discriminative parameter, detecting 20/21 AmpC producing strains. 30 
Susceptibility to third generation cephalosporines, e.g. ceftriaxone, cetazidime and cefotaxime, 31 
was found in 9 of the 21 AmpC positive strains. When considering the elevated zone diameter 32 
breakpoints of the 2010 CLSI guidelines 2/21 AmpC positive strains were categorized susceptible 33 
to third generation cephalosporines.  34 
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Introduction  35 
The prevalence of multidrug resistant Gram negative bacteria has continuously increased over 36 
the past years and bacterial strains producing AmpC beta-lactamases and/or extended spectrum 37 
beta-lactamases (ESBLs) are of particular concern. AmpC beta-lactamases can confer resistance 38 
to aminopenicillins, cephalosporins, oxyimino-cephalosporins (e.g. ceftriaxone, cefotaxime, 39 
ceftazidime), cephamycins (e.g. cofexitin, cefotetan) and monobactams (15). Cloxacillin and 3-40 
aminophenylboronic  acid inhibit AmpC beta-lactamases (2, 15, 36), while AmpC beta-lactamase 41 
activity is not affected by the ESBL inhibitor clavulanic acid. In Gram negative bacteria AmpC 42 
beta-lactamase production is chromosomally- or plasmid-mediated. Chromosomal ampC genes 43 
are constitutively expressed at a low level. Some Enterobaceriaceae such as Enterobacter spp.,  44 
Citrobacter spp. and Serratia spp.,, encode an inducible ampC. In these cases, the gene is strongly 45 
induced by β-lactams such as cefoxitin and imipenem with expression mediated by the regulator 46 
AmpR. Mutations in the repressor gene ampD may lead to overproduction of AmpC beta-47 
lactamases (15). The regulation of chromosomal ampC expression in E. coli differs considerably 48 
from that in other Enterobacteriaceae. E. coli lacks ampR and thus ampC expression is not 49 
inducible (14). In E. coli, ampC is constitutively expressed at a low level (16). Various mutations 50 
in the ampC promoter/attenuator region of E. coli have been identified that result in 51 
constitutive overexpression (7, 8, 18,  22, 24, 34, 39, 40). In addition to chromosomal ampC, E. 52 
coli may carry plasmids encoding ampC (pAmpC), transferred via horizontal gene transfer and 53 
derived from the chromosomal ampC’s of other Enterobacteriaceae spp. (15). Plasmid based 54 
ampC genes are in most of the cases constitutively expressed. However, some plasmid-encoded 55 
ampCs, such as DHA-1, are inducible by β-lactams, with expression similarly regulated as inducible 56 
chromosomal ampCs. All plasmid-encoded ampC s are considered to be of significant clinical 57 
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relevance (23, 27). AmpC overproduction in addition to porin mutations of the outer membrane 58 
can reduce susceptibility to carbapenems, in particular in plasmid-mediated AmpC producers 59 
(19, 26). 60 
AmpC producers may appear susceptible to third generation cephalosporins when initially 61 
tested (27, 38, 40) and standardized procedures for the detection and identification of AmpC 62 
beta-lactamase producing strains have not been established thus far. However, proper 63 
recognition of AmpC overproducing E. coli strains is important for clinical management, as 64 
administration of beta-lactam antibiotics frequently results in therapeutic failure. For example, 65 
a recent study described the isolation of AmpC overproducing E. coli strains from patients who 66 
did not respond to oxyimino-cephalosporin therapy (34). Another study analyzed the clinical 67 
outcome of patients with bloodstream infection caused by plasmid-mediated AmpC producing 68 
Klebsiella pneumoniae and show high rates of treatment failure when cephalosporins were 69 
administered (27). 70 
Different phenotypic AmpC confirmation tests have been reported in literature (15). A recently 71 
described disk diffusion test is based on the comparison of the zone diameters around a 72 
cefoxitin disk with a cefoxitin disk supplemented with the inhibitor cloxacillin. The test was 73 
shown to have a sensitivity and a specificity of 95 % for the detection of plasmidic AmpC when 74 
investigating 127 strains of E. coli, Klebsiella spp. and Proteus spp. (36). Another AmpC 75 
confirmation test is based on antagonism phenomena using a cefoxitin susceptible indicator 76 
strain. This test was evaluated for the detection of plasmid AmpC production in species lacking 77 
chromosomal ampC (4). Reportedly, the test had a sensitivity of 100% and specificity of 98% 78 
when testing 140 isolates of Klebsiella spp., Proteus mirabilis and Salmonella sp. (4). In this 79 
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study we aimed to evaluate and compare the diagnostic performance of the two disk diffusion 80 
tests and a commercially available assay (Etest AB bioMérieux, Sweden) as a confirmation test 81 
for the detection of AmpC activity in clinical E. coli isolates with a suspicion of AmpC production. 82 
Molecular analyses were used to asses the specificity of the phenotypic assays and to 83 
characterize the genetic basis for AmpC (over)production in these strains.  84 
6 
 
Methods 85 
Clinical isolates.  86 
51 E. coli clinical strains with reduced susceptibility to amoxicillin/clavulanic acid, 87 
piperacillin/tazobactam or oxyimino-cephalosporins (ceftazidime, cefotaxime or ceftriaxone) 88 
were collected at the Institute of Medical Microbiology, Zurich over a period of two years from 89 
July 2006 until July 2008. The strains were isolated from urine (n=12), blood culture (n=12), 90 
respiratory specimens (n=8), perianal swabs (n=4), wound swabs (n=4), inguinal swabs (n=3), 91 
abscesses (n=2), tissue (n=2), vaginal swab (n=1), gastric aspirate (n=1), cerebrospinal fluid (CSF) 92 
(n=1) and unknown origin (n=1). 93 
Antibiotic susceptibility testing. 94 
Antibiotic susceptibility testing was performed using susceptibility test disks (Becton Dickinson, 95 
Germany), interpretation was done according to CLSI guidelines 2009 and 2010 (9, 10). For 96 
cefotetan susceptibility testing the AmpC Etest strip (AB bioMérieux, Sweden) was used, as 97 
described below. Susceptibility testing was performed on Müller-Hinton agar (bioMérieux, 98 
France) using McFarland 0.5 from overnight cultures followed by incubation at 35° C for 16-18 h.  99 
Phenotypic AmpC and ESBL activity testings 100 
The AmpC ETest (AB bioMérieux, Sweden) for cefotetan susceptibility was performed according 101 
the manufacturer’s instructions. The AmpC ETest consists of a strip, containing cefotetan on one 102 
end and cefotetan/cloxacillin on the other end. Ratios of the MICs of cefotetan and 103 
cefotetan/cloxacillin which are ≥ 8 are considered positive for AmpC beta-lactamase production.  104 
The cefoxitin/cloxacillin disk diffusion test was performed as described by Tan et al (36). The 105 
test is based on the inhibitory effect of cloxacillin on AmpC. In brief, 30 µg cefoxitin disks 106 
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(Becton Dickinson, Germany) were supplemented with 200 µg cloxacillin. The test strain was 107 
inoculated on Müller-Hinton agar. The diameters of the cefoxitin inhibition zones with and 108 
without cloxacillin were compared; if the difference in inhibition was ≥ 4 mm for the 109 
cefoxitin/cloxacillin disk the strain was considered positive for AmpC production.  110 
The cefoxitin /EDTA disk test was performed as described by Black et al (4). In brief, a lawn of 111 
the cefoxitin susceptible E. coli strain ATCC 25922 was inoculated on a Müller-Hinton agar plate. 112 
A 30 µg cefoxitin disk (Becton Dickinson, Germany) was placed on the bacterial lawn and flanked 113 
by two disks (A and B) containing each 20 µl of a 1:1 mixture of saline and 100X Tris-EDTA 114 
solution. Colonies of the test strain were applied to disk A, colonies of the cefoxitin susceptible 115 
E. coli strain ATCC 25922 (as negative control) were  applied to disk B. Flattening or indentation 116 
of the growth inhibition zone of the cefoxitin disk at the side of disk A containing the test strain 117 
indicated the release of AmpC beta-lactamase. 118 
To analyze  induction of the DHA plasmid-encoded AmpC,  a disk approximation assay using 119 
imipenem as an inducer and ceftazidime, cefoxitin, ceftriaxone and piperacillin/tazobactam as 120 
substrate antibiotics was used (12). 121 
For phenotypic detaction of ESBL activity and according to CLSI guidelines, the DDS test using 122 
ceftazidime, and cefotaxime (30 µg) disks with and without clavulanic acid (10 µg) (Liofilchem, 123 
Roseto degli Abruzzi, Italy). were used The bacterial test strains were inoculated on Muller-124 
Hinton agar using McFarland 0.5 followed by incubation at 35° C for 16-18 h. Diameters of 125 
inhibition zones were measured with a standard caliper. A difference in the inhibition zone of ≥ 126 
5 mm for at least one third generation cephalosporin/clavulanic acid combination versus the 127 
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corresponding third generation cephalosporin alone was considered indicative for ESBL 128 
production. 129 
Beta-lactamase hydrolysis assays 130 
For phenotypic detection of beta-lactamase activity the chromogenic nitrocefin  (Calbiochem, 131 
San Diego, USA) was used (35). 3-aminophenylboronic acid (Sigma-Aldrich Chemie, GmbH, Zug, 132 
Switzerland) was used as specific AmpC inhibitor (2) and clavulanic acid (Sigma-Aldrich Chemie, 133 
GmbH, Zug, Switzerland) was used as inhibitor of Ambler class A β-lactamases (e.g. ESBL, TEM-1) 134 
(5). A bacterial suspension McFarland standard 0.5 in 0.45% NaCl was prepared from overnight 135 
cultures. E. coli strain DH5α was used as negative control strain. Reaction mixtures consisted of 136 
50 μl bacterial cell suspension, 25 μl nitrocefin (0.5 mg/ml 10 mM phosphate buffer pH 6.8), 25 137 
μl 3-aminophenylboronic acid (3.6 mg/ml 10 mM phosphate buffer pH 6.8) and/or 25 μl 138 
potassium clavulanate (2.2 mg/ml 10 mM phosphate buffer pH 6.8). In case 3-139 
aminophenylboronic acid and/or clavulanic acid were not added, the end volume of 125 μl was 140 
reached by adding 10 mM phosphate buffer pH 6.8. Reaction mixtures were incubated in micro 141 
titerplates at 37 
o
C. The nitrocefin hydrolyis product was detected by quantifying the absorption 142 
after 8 hours at OD492nm using a titerplate photospectrometer (Biochrom Asys Expert Plus 143 
Microplate Reader, Biochrom Ltd, Cambridge, UK) 144 
 145 
ampC promoter/attenuator sequencing. DNA was extracted from colonies grown on agar 146 
medium using the InstaGene Matrix (Bio-Rad, Switzerland) following the manufacturer’s 147 
instructions. For the ampC promoter/attenuator mutation analysis a 271-bp fragment was 148 
amplified using primers AB1(5’-GATCGTTCTGCCGCTGTG-3’) and ampC2 (5’-149 
9 
 
GGGCAGCAAATGTGGAGCAA-3’) (11). PCR amplicons were purified with the QIAquick PCR 150 
purification kit (Qiagen, Switzerland) followed by cycle sequencing using the BigDye reagent kit 151 
(Applied Biosystems, Switzerland). Sequence analysis was performed on an ABI Prisma 3100 152 
DNA sequencer (Applied Biosystems, Switzerland) following standard protocols. Sequences 153 
were analyzed and edited using Lasergene 7 MegAlign software (DNASTAR Inc., USA). The ampC 154 
promoter/attenuator sequences were compared to the ampC wild-type sequence of E.coli strain 155 
ATCC 25922.  156 
Molecular detection of plasmid-encoded ampC beta-lactamase genes.  157 
A multiplex PCR was used for the detection of plasmid-encoded ampC beta-lactamase genes 158 
(29). This assay is able to detect the six plasmid-encoded ampC genes families. Resulting PCR 159 
amplicons were sequenced with the amplification primers following the protocol described 160 
above. The sequences were compared to reference sequences in the NCBI Genbank (National 161 
Center for Biotechnology Information (GenBank),http://www.ncbi.nlm.nih.gov/).  162 
Detection of ESBL and Klebsiella carbapenamase (KPC) genes 163 
For detection of TEM and SHV beta lactamase genes a multiplex PCR was performed as 164 
described previously  (21). Sequences were analyzed and edited using Lasergene 7 MegAlign 165 
software (DNASTAR Inc., USA). The TEM beta-lactamases sequences were compared to wt E. coli 166 
AF427133.1 TEM-1 using the publicly available database at http://www.lahey.org/studies. For 167 
the detection of CTX-M beta-lactamase genes a multiplex PCR was performed as described by 168 
Pitout et al., 2004.  For detection of a Klebsiella carbapenamase (KPC) gene a PCR was used as 169 
described  previously (33). 170 
 171 
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Interpretation.  172 
E. coli strains positive for AmpC activity in at least one phenotypic test (AmpC ETest, AmpC 173 
cefoxitin/EDTA disk test, AmpC cefoxitin/cloxacillin disk test) validated by genetic analysis 174 
(presence of plasmid-encoded ampC genes, ampC promoter/attenuator mutations associated 175 
with chromosomal ampC overexpression) were considered to be true AmpC producers. Strains 176 
with discrepant test results were analyzed in further detail for β-lactamase production using 177 
nitrocefin hydrolysis assays, phenotypic ESBL assays, molecular assays for ESBL and KPC 178 
detection and sequence analysis of detected TEM and SHV genes. 179 
 180 
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Results  181 
Phenotypic screening for AmpC production. 182 
For 18/51 (35 %) of the E. coli isolates all three phenotypic tests gave a positive result for AmpC 183 
production (Table 1). The ratios of the AmpC ETest ranged from 8 to 64. In the AmpC 184 
cefoxitin/cloxacillin disk test the differences in zone diameters ranged from 4 mm to 14 mm 185 
(Table 1). For 28/51 (55 %) of the E. coli strains negative results were obtained in all three 186 
phenotypic assays (Table 2). In these strains the ratio of the AmpC ETest ranged from 1 to 4 and 187 
the differences in zone diameters of the cefoxitin/cloxacillin disk test measured were 0 mm 188 
(n=22), 1 mm (n=4), 2 mm (n=1) and 3 mm (n=1) (Table 2). Molecular testing confirmed the 189 
results of the concordant phenotypic testing (18/18 positives and 28/28 negatives).  190 
Discrepant test results were obtained for 5/51 (10 %) of the isolates, i.e. strains 19, 20, 21, 22 191 
and 23. The analysis of the discrepant test results and their resolution is given in detail below. 192 
Strain no. 19 was positive in the AmpC ETest (ratio=32), negative in the AmpC 193 
cefoxitin/cloxacillin disk diffusion test (difference in zone diameter 0 mm) and positive in the 194 
AmpC cefoxitin /EDTA disk diffusion test. In this strain, the ampC promoter/attenuator 195 
sequence showed mutations associated with upregulation of the chromosomal ampC gene 196 
expression (sequence variant 3; Table 3).  Strain no. 20 was negative in the AmpC ETest (ratio=1) 197 
and positive in both AmpC disk diffusion tests, the difference in zone diameter for the AmpC 198 
cefoxitin/cloxacillin disk diffusion test was 6 mm. Genetic analysis showed promoter/attenuator 199 
mutations associated with chromosomal ampC overexpression (variant 4; Table 3) (7, 16, 40). 200 
Strain no. 21 was negative in the AmpC ETest (ratio=1.5), negative in the AmpC cefoxitin /EDTA 201 
disk diffusion test, but positive in the AmpC cefoxitin/cloxacillin disk diffusion test (diameter 202 
12 
 
difference 4 mm). The ampC promoter and attenuator region of strain no. 21 resembles that of 203 
the wildtype E. coli K12 strain. The multiplex PCR for plasmid-meditated ampC genes was 204 
positive for DHA. Induction of the DHA gene in strain no. 21 was revealed by a disk 205 
approximation assay (12) using imipenem as inducer and ceftazidime, cefoxitin, ceftriaxone and 206 
piperacillin/tazobactam as substrate antibiotics. Nitrocefin hydrolysis assays showed that β-207 
lactamase activity of strains no. 19, 20 and 21 was inhibited by the AmpC inhibitor 3-208 
aminophenylboronic acid (Table 4). Phenotypic assays for ESBL detection  (DDS assay) revealed 209 
that strains no. 19 and 20 were ESBL negative and strain 21 was ESBL positive, which was 210 
confirmed by the identification of a CTXM-1 gene in strain 21.  A non-ESBL TEM-1 β-lactamase 211 
was detected in strain no. 19 and 21. A corresponding inhibitory effect of the TEM-1 inhibitor 212 
clavulanic acid on hydrolysis of nitrocefin was detected in strains no. 19 and 21, whereas strain 213 
20 did not show such an inhibitory effect. A KPC PCR was negative for strains no. 19, 20 and 21. 214 
(for a summary of the results see Table 4). Based on our interpretation criteria and the 215 
additional β-lactamase analyses strains no. 19, 20 and 21 were considered true AmpC producers 216 
(Table 1).  217 
Two strains (no. 22 and 23) were positive in the AmpC cefoxitin /EDTA disk diffusion test and 218 
negative in AmpC cefoxitin/cloxacillin disk diffusion test and the AmpC ETest. Both strains were 219 
negative for plasmid-encoded ampC genes and genetic analysis of the ampC 220 
promoter/attenuator region did not reveal mutations typically associated with chromosomal 221 
ampC up regulation. Additional β-lactamase analysis for strains no. 22 and 23 showed that 222 
nitrocefin hydrolysis was not inhibited by the AmpC inhibitor 3-aminophenylboronic acid (Table 223 
4). Phenotypic ESBL testing (DDS assay) revealed that strains no. 22 was ESBL positive and no. 23 224 
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was ESBL negative, which was confirmed by the identification of a CTXM-1 gene in strain 22.  A 225 
TEM-1 β-lactamase was detected in strain no. 23. A corresponding inhibitory effect of clavulanic 226 
acid on hydrolysis of nitrocefin was detected in both strains.  KPC PCR was negative for strains 227 
no. 22 and 23 (see Table 4). Based on our interpretation criteria and the additional β-lactamase 228 
analyses, strains no. 22 and 23 were considered AmpC negative (Table 2).  229 
In total, 21/51 (41 %) of the E. coli strains investigated in this study were considered AmpC 230 
producers and 30/51 (59 %) were negative for AmpC production (Table 1 and Table 2). The 231 
AmpC ETest detected 19/21 (90.5 %) correctly positive and showed no false positive results. The 232 
AmpC cefoxitin/cloxacillin disk test was correctly positive in 20/21 (95.2%) AmpC positive strains 233 
and did not result in false positive results. The AmpC cefoxitin /EDTA disk test was correctly 234 
positive in 20/21 (95.2%) strains and gave two false positive results.  235 
ampC promoter/attenuator mutations and plasmid-encoded ampC beta-lactamases.  236 
In the 51 E. coli strains 15 different ampC promoter/attenuator sequence variants were 237 
detected (Figure 1). For the 21 AmpC positive strains 10 different promoter/attenuator 238 
sequence variants 1, 2, 3, 4, 5, 6, 11, 12, 14 and 15 were found (Table 3). Promoter/attenuator 239 
sequence variants 1, 2, 3, 5, 6 were found in 11 strains with a positive AmpC production 240 
phenotype and negative for plasmid-encoded ampC. Sequence variant 5 comprises two AmpC 241 
positive strains, one positive for plasmid-encoded ampC genes and one negative strain for 242 
plasmid-encoded ampC. Mutations detected in sequence variants 1, 2, 3, 4, 5 and 6 included (i) 243 
mutations that created an alternate displaced promoter (variants 1 and 2), (ii) mutations in the 244 
wildtype promoter/attenuator (variants 3 and 4) and (iii) mutations that increased the spacer 245 
length between the -35 and -10 box (variants 5 and 6) by insertion of 1 or 2 basepairs. The 246 
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mutations found in these sequence variants are associated with an increase of ampC expression 247 
(11). Sequence variants 11, 12, 14, and 15 were found in phenotypic AmpC positive strains, 248 
which were all positive for the presence of plasmid-encoded ampC genes. Mutations in these 249 
sequence variants were located in the attenuator region, the coding region of AmpC or resulted 250 
in an alternate displaced -10 box. None of these changes has been reported to be associated 251 
with significant chromosomal AmpC overproduction (see below). Variant no. 14 resembles the 252 
wildtype E. coli K12 ampC promoter/attenuator (Table 3). In total, 13/21 AmpC positive strains 253 
harbored changes in the promoter/attenuator region typically associated with chromosomal 254 
AmpC overproduction (32).  255 
Plasmid-encoded ampC genes were detected in 9 of the 21 strains. In 1 strain both 256 
chromosomal and plasmid-mediated mechanisms responsible for AmpC production were 257 
found., e.g. a two bp insertion in the spacer of the ampC chromosomal promoter/attenuator 258 
region and a plasmid encoded ampC gene (Table 3). The plasmid-encoded ampC genes found in 259 
the isolates belonged to the CIT family (n=8) and the DHA family (n=1). Sequences of the PCR 260 
product showed 100% homology to the blaCMY-2 gene for the CIT family isolates and 100% 261 
homology to the blaDHA-1 gene for the DHA family isolate (data not shown). 262 
 263 
Susceptibility to amoxicillin/clavulanic acid, piperacillin/tazobactam, cefoxitin and third-264 
generation cephalosporins. 265 
All 21 AmpC positive strains showed reduced susceptibility to amoxicillin/clavulanic acid. 20 of 266 
21 strains were tested resistant, one strain was intermediate. In contrast, only 1/21 strains was 267 
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resistant to piperacillin/tazobactam, 6/21 isolates showed an intermediate level and 14/21 268 
strains were tested susceptible.  269 
For third-generation cephalosporins the following test results were obtained for the 21 AmpC 270 
positive strains applying the 2009 CLSI guideline (9) zone diameter breakpoints: ceftazidime (11 271 
strains susceptible, 3 strains intermediate and 7 strains resistant), cefotaxime (9 strains 272 
susceptible, 7 strains intermediate and 5 strains resistant) and ceftriaxone (12 strains 273 
susceptible, 4 strains intermediate and 5 strains resistant). All AmpC positive strains were 274 
susceptible to cefepime (Table 1). Resistance patterns for AmpC negative strains are 275 
summarized in Table 2. In 2010 the CLSI zone diameter breakpoints for ceftazidime, cefotaxime 276 
and ceftriaxone were elevated (10). Applying these breakpoints resulted in the following 277 
interpretation of susceptibility testing for AmpC positive strains: ceftazidime (susceptible 5 278 
strains, intermediate 6 strains and resistant 10 strains), cefotaxime (susceptible 2 strains, 279 
intermediate 7 strains and resistant 12 strains) and ceftriaxone (susceptible 9 strains, 280 
intermediate 3 strains and resistant 9 strains) (supplemental material Table 1A). Results for the 281 
AmpC negative strains are summarized in supplemental material Table 1B.  282 
By disk diffusion susceptibility testing and according to CLSI guidelines 2009, 17/21 AmpC 283 
producing strains (81 %) were resistant to cefoxitin, 3/21 strains were intermediate and 1/21 284 
strain was susceptible (inhibition zone diameter 18 mm) (Table 1). 28/30 AmpC negative strains 285 
(93 %) were susceptible to cefoxitin, for 1/30 strains an intermediate result was obtained and 286 
1/30 strains was resistant (Table 2). 287 
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Discussion 288 
Detection of AmpC beta-lactamases in E. coli poses a challenge to microbiological laboratories. 289 
For practical reasons it is not feasible to routinely test all E. coli isolates for AmpC production in 290 
detail. In our study we selected 51 E. coli clinical isolates collected during a two-year period for 291 
putative AmpC production based on reduced susceptibility to amoxicillin/clavulanic acid, 292 
piperacillin/tazobactam or oxyimino-cephalosporins (ceftriaxone, ceftazidime, cefotaxime). 293 
Several AmpC confirmation tests have recently been evaluated (4, 36) or became commercially 294 
available (AmpC Etest, AB bioMérieux). In this study we compared the performance of three of 295 
these tests for accurate identification of AmpC producing E. coli strains, i.e. AmpC ETest (AB 296 
bioMérieux, Sweden), AmpC cefoxitin /cloxacillin disk test (36), and AmpC cefoxitin /EDTA disk 297 
test (4). AmpC producing E. coli strains were validated by genetic analyses. In addition, strains 298 
with discrepant AmpC screening results were further analyzed for β-lactamase production by 299 
nitrocefin hydrolysis assays, ESBL phenotypic testing, genetic testing for the presence of SHV, 300 
TEM, CTX-M β-lactamases and KPC (Table 4). The additional test results confirmed the accuracy 301 
of our interpretation criteria for AmpC production.  In total, 21 of the selected 51 E. coli isolates 302 
were identified as true AmpC producing strains (plasmidic ampC n=8, overexpression of 303 
chromosomal ampC n=12, combination of plasmidic ampC and overexpression of chromosomal 304 
ampC  n=1). We found that the cefoxitin /cloxacillin disk test detected 20/21 AmpC positive E. 305 
coli strains (Table 1) and gave 1 false negative result. The cefoxitin /EDTA disk test (4) detected 306 
20/21AmpC positive strains and gave 1 false negative result and 2 false positive results. A 307 
drawback of the cefoxitin /EDTA disk assay is that carbapenemases may give rise to false 308 
positive results as carbapenamases are able to inactivate cefoxitin (4), although KPC was not 309 
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detected in the 2 false positive strains. The AmpC Etest strip uses cefotetan for AmpC screening. 310 
While cefotetan resistance (R > 64 mg/l) was not consistently present in the AmpC positive 311 
strains (Table 1), the AmpC Etest was able to detect 19/21 strains correctly positive,  2 strains 312 
gave a false negative test result. 313 
The ampC promoter/attenuator mutations detected in the 51 E. coli isolates (Table 3)  included 314 
6 previously described variants associated with ampC overexpression (references 7, 16, 17, 24, 315 
34, 40). Overall, 13/21 (61.9%) positive AmpC strains were associated with chromosomal ampC 316 
promoter mutations resulting in hyperproduction of AmpC and 9/21 strains (42.9%) were AmpC 317 
positive due to the presence of plasmid-encoded ampC genes. One strain had a two basepair 318 
insertion in the ampC promoter spacer region (variant 5) and a plasmid-encoded ampC gene; 319 
both mechanisms may have contributed to AmpC activity in this strain. The observed ratio of 320 
AmpC production due to chromosomal ampC upregulation versus plasmid-mediated AmpC is in 321 
accordance with the distribution observed in studies conducted in France, Spain and Norway (6, 322 
13, 20). We did not detect any strain that was positive in the genetic analysis and negative in all 323 
three phenotypic confirmation tests. 324 
As the cefoxitin and cefotetan based AmpC disk assays effectively identify AmpC producers we 325 
decided to evaluate whether cefoxitin and cefotetan susceptibility testing can be used as a 326 
screening test for AmpC production. In the group of AmpC positive strains 20 of 21 (95%) 327 
isolates were resistant or intermediate in the cefoxitin disk test. One strain showed an inhibition 328 
zone of 18 mm which is just within the susceptible range (Table 1). For the AmpC negative 329 
strains 26 of 30 (87%) strains were susceptible to cefoxitin with inhibition zones > 18 mm. Two 330 
strains scored within the susceptible range with inhibition zones of 18 mm, one strain was 331 
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intermediate and one strain was resistant to cefoxitin (Table 2). Applying a screening criterium 332 
of cefoxitin inhibition zone ≤ 18 mm, all AmpC positive strains would have been detected plus 333 
an additional 4 false positives. However, the use of cefoxitin as screening marker is 334 
compromised by isolates producing plasmid-encoded AmpC beta-lactamases of the ACC family. 335 
ACC-1 itself is inhibited by cefoxitin and thus may appear cefoxitin susceptible (1, 15, 32). ACC-1 336 
has first been isolated in Germany and in several other European countries. (1, 25, 31, 32). 337 
Recently, AmpC betalactamase ACC-4 was identified in E. coli, conferring increased MICs for 338 
oxyimino-cephalosporins with low MICs for cefoxitin and cefepime (28). In our study, strains 339 
with a plasmid ACC beta-lactamases gene were not detected.  340 
Analyzing cefotetan MICs in the AmpC ETest revealed that 2 of the 21 (10%) AmpC positive 341 
strains were resistant to cefotetan. 10 of 21 (48%) of the AmpC positive strains were susceptible 342 
to cefotetan and intermediate results were obtained for 9 (42%) isolates (Table 1). On the basis 343 
of these results we can not recommend cefotetan susceptibility for initial AmpC screening. 344 
We also evaluated whether reduced sensitivity to third generation cephalosporins can be used 345 
as screening parameter for AmpC testing. Several studies showed that cephalosporine 346 
susceptibility screening of E. coli isolates with the initial purpose of ESBL identification resulted 347 
in selection for AmpC producing strains (3, 23). Nine of the 21 (43%) AmpC positive strains were 348 
susceptible to ceftazidime, cefotaxime and ceftriaxone in vitro according to the CLSI 2009 349 
guidelines. Another two strains were susceptible to ceftazidime and ceftriaxone and one strain 350 
was susceptible to ceftriaxone only (Table 1). Applying the elevated CLSI 2010 zone diameter 351 
breakpoints two strains were susceptible to ceftazidime, cefotaxim and ceftriaxone; another 352 
two strains were susceptible to ceftazidime and ceftriaxone, one strain was susceptible to 353 
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ceftazidime only and five strains were susceptible to ceftriaxone only (supplemental material 354 
Table 1A). On the basis of our results we cannot recommend third generation cephalosporins as 355 
screening parameters for AmpC . 356 
In summary, we demonstrate that after a first screening procedure each of the three 357 
phenotypic AmpC tests used in this study was capable to confirm the majority of AmpC beta-358 
lactamase producing E. coli strains (>90 %) including plasmid-mediated AmpC beta-lactamases 359 
and chromosomal AmpC hyperproduction strains. Each of the three tests is an acceptable 360 
phenotypic confirmation tool when AmpC production is suspected in E. coli.  361 
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 AmpC ETest 
AmpC disk test 
cefoxitin/cloxacillin 
AmpC disk test 
cefoxitin/EDTA ampC plasmid PCR
c
   ampC chrom
d
 final AmpC assignment 
e
 Antibiotic resistance disk testing (mm)f 
strain 
no. 
cefotetan MIC 
(µg/ml) Ratio
a
 AmpC 
difference 
(mm)b AmpC  AmpC (class) 
(promoter 
variant)  CAZ CTX CRO FEP AMC TZP FOX 
1 S (12) 24 positive 8 positive positive negative positive (1) positive S (18) S (23) S (23) S (29) R (7) S (21) R (7) 
2 S (4) 8 positive 8 positive positive negative positive (1) positive S (21) I (22) S (21) S (27) R (10) S (23) R (12) 
3 I (32) 43 positive 8 positive positive negative positive (1) positive R (12) I (19) S (21) S (28) R (7) I (20) R (7) 
4 I (32) 64 positive 11 positive positive negative positive (1) positive S (21) S (24) S (26) S (30) R (7) I (20) R (13) 
5 I (32) 21 positive 5 positive positive negative positive (1) positive S (20) I (19) S (21) S (26) I (16) S (22) R (7) 
6 S (12) 24 positive 5 positive positive negative positive (1) positive S (18) S (25) S (26) S (28) R (7) I (18) I (15) 
7 S (4) 8 positive 8 positive positive negative positive (3) positive S (28) S (27) S (28) S (32) R (11) S (26) I (17) 
8 S (24) 48 positive 5 positive positive negative positive (2) positive S (19) S (23) S (23) S (30) R (7) I (19) S (18) 
9 S (16) 32 positive 10 positive positive negative positive (5) positive S (20) S (23) S (25) S (32) R (10) S (23) R (13) 
10 S (12) 24 positive 6 positive positive negative positive (6) positive S (19) S (25) S (28) S (29) R (12) S (21) R (14) 
11 R (>32) 8 positive 5 positive positive positive (CITg) negative (12) positive R (7) R (7) R (7) S (24) R (7) I (18) R (7) 
12 R (>32) 8 positive 4 positive positive positive (CIT)  negative (12) positive R (7) R (7) R (7) S (20) R (7) R (14) R (7) 
13 I (32) 8 positive 9 positive positive positive (CIT) negative (12) positive R (7) R (10) R (7) S (25) R (7) I (20) R (7) 
14 I (32) 64 positive 13 positive positive positive (CIT) negative (15) positive I (15) I (15) I (16) S (29) R (7) S (21) R (7) 
15 I (32) 64 positive 14 positive positive positive (CIT) negative (15) positive I (16) I (17) I (16) S (25) R (10) S (25) R (7) 
16 I (32) 64 positive 10 positive positive positive (CIT) negative (11) positive R (7) R (14) R (12) S (28) R (10) S (21) R (7) 
17 S (8) 16 positive 10 positive positive positive (CIT) negative (11) positive I (17) I (20) I (18) S (26) R (11) S (24) R (9) 
18 I (32) 43 positive 10 positive positive positive (CIT) positive (5) positive R (7) I (18) I (15) S (28) R (7) S (22) R (7) 
19 I (32) 32 positive 0 negative positive negative positive (3) positive S (23) S (25) S (26) S (31) R (10) S (24) R (14) 
20 S (0.5) 1 negative  6 positive positive negative positive (4) positive S (26) S (28) S (37) S (28) R (12) S (25) I (17) 
21 S (0.75) 2 negative 4 positive negative positive (DHAh) negative (14) positive R (11) R (13) R (7) S (18) R (9) S (23) R (7) 
 535 
Table 1. Characterization of 21 E. coli strains positive for AmpC activity.  536 
Strains were analyzed for AmpC production using three phenotypic confirmation AmpC assays. Genetic analysis for AmpC 537 
production was done by multiplex PCR for plasmid ampC detection and sequence analysis of the chromosomal ampC 538 
promoter/attenuator region. In addition, for each strain antimicrobial susceptibility data were generated. Strains with 539 
discrepant results in the three phenotypic confirmation AmpC assays are assays are highlighted in grey. 540 
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Abbreviations: S, susceptible; R, resistant; I, intermediate; AMC, amoxicillin-clavulanic acid; CAZ, ceftazidime; CRO, 541 
ceftriaxone; CTT, cefotetan; CTX, cefotaxime; FEP, cefepime; FOX, cefoxitin; TZP, piperacillin-tazobactam; 542 
a. Ratio of MIC cefotetan to cefotetan/cloxacillin is determined in the AmpC ETest (ratios ≥ 8 are considered AmpC positive). 543 
b. Difference between diameters in the cefoxitin inhibition zones with and without cloxacillin were determined (increase ≥ 4 544 
mm for the cefoxitin/cloxacillin disk is considered AmpC positive).  545 
c. Plasmid-mediated ampC was detected by multiplex PCR (29). 546 
d. For ampC promoter /attenuator sequence variants see Figure 1. 547 
e. A final assigment for AmpC activity combining phenotypic and genetic results was made according to the definition 548 
specified in the ‘Materials and Methods’. A strain was scored positive when at least one phenotypic test was positive, which 549 
was validated by genetic analysis (plasmid-encoded ampC, ampC promoter mutations associated with ampC 550 
overexpression). 551 
f. Diameter of growth inhibition zone in mm. The zone diameter breakpoints of the 2009 CLSI guidelines were applied (9).  552 
g. CIT: plasmid-encoded ampC originating from Citrobacter freundii. 553 
h. DHA: plasmid-encoded ampC originating from Morganella morganii. 554 
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 555 
 AmpC ETest 
AmpC disk test 
cefoxitin/cloxacillin 
AmpC disk test 
cefoxitin/EDTA plasmid ampC PCR
c
 AmpC chrom 
d
 final AmpC assignment
e
 Antibiotic resistance disk testing (mm)f 
strain 
no. 
cefotetan 
MIC (µg/ml) Ratio
a
 AmpC  
difference 
(mm)b AmpC  AmpC   Promoter variant  CAZ CTX CRO FEP AMC TZP FOX 
22 S (2) 1 negative 0 negative positive negative negative (10) negative R (14) R (7) R (7) I (15) R (13) S (23) I (16) 
23 S (3) 2 negative 0 negative positive  negative negative (8) negative S (30) S (26) S (25) S (29) I (16) S (22) R (12) 
24 S (0.5) 1 negative 0 negative negative negative negative (12) negative S (28) S (25) S (29) S (28) I (16) S (22) S (25) 
25 S (0.75) 1 negative 0 negative negative negative negative (15) negative S (23) S (28) S (23) S (24) R (10) R (9) S (24) 
26 S (0.5) 1 negative 0 negative negative negative negative (15) negative S (20) S (28) S (27) S (28) R (10) I (18) S (20) 
27 S (2) 1 negative 0 negative negative negative negative (15) negative S (22) S (29) S (26) S (27) R (7) R (7) S (20) 
28 S (1) 1 negative 3 negative negative negative negative (15) negative S (22) S (25) S (26) S (25) I (17) S (23) S (27) 
29 S (0.5) 1 negative 0 negative negative negative negative (15) negative S (29) S (28) S (28) S (33) I (14) S (21) S (24) 
30 S (0.5) 1 negative 0 negative negative negative negative (11) negative S (26) S (28) S (26) S (26) R (10) I (18) S (23) 
31 S (0.5) 1 negative 0 negative negative negative negative (11) negative S (28) S (25) S (25) S (24) R (7) R (14) S (25) 
32 S (0.5) 1 negative 0 negative negative negative negative (11) negative S (26) S (32) S (28) S (30) R (12) R (14) S (30) 
33 S (0.5) 1 negative 0 negative negative negative negative (10) negative S (27) S (23) S (25) S (26) R (10) R (15) S (21) 
34 S (0.5) 1 negative 0 negative negative negative negative (10) negative S (28) S (25) S (28) S (28) I (15) S (23) S (21) 
35 S (0.5) 1 negative 0 negative negative negative negative (8) negative S (26) R (7) R (7) S (23) S (19) R (7) S (24) 
36 S (0.5) 1 negative 0 negative negative negative negative (7) negative S (20) R (7) R (7) I (17) R (10) R (14) S (23) 
37 S (0.5) 1 negative 0 negative negative negative negative (7) negative S (25) I (19) I (14) S (25) I (15) I (20) S (24) 
38 I (32) 1 negative 0 negative negative negative negative (7) negative R (7) R (7) R (7) R (7) R (7) R (7) S (18) 
39 S (0.5) 1 negative 0 negative negative negative negative (7) negative S (24) I (19) R (7) S (25) R (11) I (18) S (23) 
40 S (0.75) 1 negative 0 negative negative negative negative (7) negative S (26) I (20) R (7) S (26) R (13) S (22) S (25) 
41 S (0.5) 1 negative 0 negative negative negative negative (7) negative S (25) R (7) R (7) R (13) I (14) R (7) S (28) 
42 S (0.5) 1 negative 0 negative negative negative negative (14) negative S (25) S (25) S (28) S (25) I (15) S (23) S (22) 
43 S (0.5) 1 negative 0 negative negative negative negative (14) negative S (27) S (28) S (28) S (26) I (14) S (23) S (25) 
44 S (0.5) 1 negative 1 negative negative negative negative (15) negative S (29) S (33) S (26) S (31) R (13) S (22) S (28) 
45 S (0.5) 1 negative 1 negative negative negative negative (14) negative S (26) S (28) S (27) S (28) I (17) S (21) S (21) 
46 S (1.5) 1 negative 1 negative negative negative negative (9) negative S (21) S (27) S (25) S (25) R (10) R (10) S (19) 
47 S (0.5) 1 negative 2 negative negative negative negative (13) negative S (26) I (15) I (15) S (22) I (17) S (25) S (30) 
48 S (0.75) 2 negative 0 negative negative negative negative (7) negative S (26) I (18) I (16) S (24) I (16) I (18) S (25) 
49 S (0.75) 2 negative 0 negative negative negative negative (7) negative S (25) I (20) S (25) I (15) R (7) R (10) S (24) 
50 S (0.75) 2 negative 0 negative negative negative negative (14) negative S (25) S (28) S (26) S (25) I (17) I (20) S (18) 
51 S (8) 4 negative 1 negative negative negative negative (14) negative S (26) S (27) S (26) S (25) R (13) I (18) S (21) 
Table 2. Characterization of the 30 E. coli strains negative for AmpC activity. Interpretation of susceptibility results according 556 
to the CLSI guideline 2009.  557 
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Strains were analyzed for AmpC production using three phenotypic AmpC assays. Genetic analysis for AmpC production 558 
was done by multiplex PCR for plasmid ampC detection and sequence analysis of the chromosomal ampC 559 
promoter/attenuator region. In addition, for each strain  antimicrobial susceptibility data were generated. Strains with 560 
discrepant results in the three phenotypic confirmation AmpC assays are highlighted in grey. 561 
For abbreviations see legend Table 1. 562 
Footnotes a. to f. see Table 1.  563 
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 564 
promoter 
sequence 
varianta 
E.coli 
strain no. 
number. 
of strains 
(n=51) 
number of 
AmpC 
positive 
strains (%) 
number of 
strains carrying 
plasmid-
mediated ampC 
a) b)
 position(s) of 
mutations in ampC 
promoter/attenuator region 
b)
 localization and function of mutations 
1 1, 2, 3, 4, 5, 6 6 6 (100%) - -42, -18, (-1), (+58), +81 alternate displaced promoter (-35 box and -10 box) and mutations in the AmpC coding region 
2 8 1 1 (100%) - -42, -18, -15, (-1), (+58), +81 alternate displaced promoter (-35 box and -10 box) and mutations in the AmpC coding region 
3 7, 19 2 2 (100%) - -32, +81 promoter mutation and mutation in the AmpC coding region 
4 20 1 1 (100%) - -32, -28, +17 promoter mutation,  mutations in the spacer region and in the AmpC coding region 
5 9, 18 2 2 (100%) 1 INS (-13.1), INS (-13.2) Increased distance between -35 and -10 box 
6 10,16 1 1 (100%) - -14, INS (-13.1), +81 Increased distance between -35 and -10 box, promoter mutation and mutation in the ampC 
coding region 
7 
36, 37, 38, 
39,40, 
41,48, 
8 none - -28 mutation in the spacer region 
8 23, 35 2 none - -28, (+58) mutation in the spacer region 
9 46 1 none - -28, +17 mutation in the spacer region and mutation in the attenuator 
10 22, 33, 34 3 none - -28, +34, (+58) mutation in the spacer, attenuator mutation and mutation in the coding region ampC 
11 16, 17, 30, 31, 32 5 2 (40%) 2 -18, (-1), (+58), +81 alternate displaced promoter (-10 box only) and mutation in the coding region ampC 
12 11, 12, 13, 24 4 3 (75%) 3 +22, +26, +27, +32, +70, +81 attenuator mutations and mutations in the coding region ampC 
13 47 1 none - (+58), +63 mutation in the coding region ampC 
14 21, 42, 43, 45, 50, 51,  6 1 (17%) 1 +81 mutation in the coding region ampC 
15 
14, 15, 25, 
26, 27, 28, 
29, 44 
8 2 (25%) 2 +70, +81 mutations in the coding region ampC 
 565 
Table 3 Genetic characterization of the 51 E.coli isolates by ampC promoter region sequence analysis and multiplex PCR for 566 
detection of plasmid-mediated ampC. All isolates with promoter sequence variants 1, 2, 3, 4, 5 and 6 are considered positive 567 
for AmpC activity due to chromosomal overexpression of ampC. Promoter variants 11, 12, 14 and 15 are found in 568 
phenotypically AmpC positive and AmpC negative strains; the AmpC positive strains all harboured plasmid-encoded AmpC. 569 
Promoter sequence variants 7, 8, 10 and 13 were not associated with increased phenotypic AmpC activity. 570 
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a. Analysis of ampC promoter/attenuator mutations (for detailed sequence analysis see Figure 1). 571 
b. Mutations and mechanisms resulting in overexpression leading to ampC upregulation are typed in bold and highlighted in 572 
grey. Insertion of nucleotides is marked with INS. Mutations outside functional promoter elements are displayed in brackets 573 
(4). 574 
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Table 4. Characterization of β-lactamase activity in E. coli strains (n=5) considered false positive or false negative in phenotypic 575 
screening for AmpC overproduction. 576 
E. coli strain 
a
 Nitrocefin hydrolysis (ODnm=492)
b
 ESBL 
c
 KPC
d
 
 Without 
inhibitor 
aminophenylboronic  
acid 
clavulanic acid boronic acid and 
clavulanic acid 
phenotypic genetic  
   Inhibition  Inhibition  Inhibition    
19 0.309 
 ± 0.006 
0.106 
±0.008 
+ 0.080  
±0.010 
+ 0.041 
±0.004 
+ - (TEM-1) - 
20 0.151  
± 0.014 
0.006  
±0.005 
+ 0.120 
±0.008 
- 0.015 
±0.006 
+ - - - 
21 0.344  
± 0.020 
0.225  
±0.002 
+ 0.083 
±0.0 
+ 0.051 
±0.006 
+ + (TEM-1)/ 
CTXM-1 
- 
22 0.777  
±0.007 
0.847  
±0.015 
- 0.332 
±0.006 
+ 0.395 
±0.009 
+ + CTXM-1 - 
23 0.366  
±0.005 
0.314  
±0.005 
- 0.074 
±0.001 
+ 0.066 
±0.007 
+ - (TEM-1) - 
a. Strain numbers correspond to Tables 1 and 2. 577 
b.  Nitrocefin hydrolysis was tested in absence and presence of boronic acid (as specific AmpC inhibitor) and/or clavulanic acid (as 578 
specific ESBL and TEM-1 inhibitor). Presented values are the average of duplicate reactions. 579 
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c. ESBL were phenotypically detected by the DDS test as described in Material and Methods. PCR detection of TEM, SHV and CTX-580 
M genes were done  as described previously (21, 30). Note: TEM-1 is not an ESBL β-lactamase, but is able to hydrolyse nitrocefin. 581 
Therefore the detection of TEM-1 is shown inbrackets 582 
d. PCR detection  of KPC  genes was performed as described previously (33). 583 
Figure 1 Alignment of the chromosomal ampC promotor, attenuator and 5`-end regions. For the 51 E. coli isolates, 15 different sequence variants were
identified. * The chromosomal ampC sequence variant classification and description of functional elements was used according Tracz et al. (40).
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